CPHI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Login
View profile
Log out
Welcome back

Click below to sign in and see leads, RFIs or statistics

Sign in

Sign out
- Search Impressions
  
  3 287
- Page views
  
  324
- Request for information
  
  54

News

5 Nov 2012

Average drug company spends $237k per medical science liaison

Cutting Edge Information's latest report sheds light on pharmaceutical companies' expenditure on MSL teams.

Drug companies in the US spend an average of $237,000 on each of their medical science liaisons (MSLs), a new study has shown.

An MSL is a healthcare consulting professional who is employed by a pharmaceutical or medical device company to communicate with clinicians and medical facilities.

Related News

News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025

German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.

20 Dec 2023
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests

A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test.

17 Oct 2023
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m

To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development.

16 Oct 2023
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond

The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders.

18 Sep 2023
News Is patient centricity the future of pharmaceutical manufacturing?

In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare.

25 Aug 2023
News CPHI Podcast Series: How to leverage AI for Drug Discovery

Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare.

17 Aug 2023
News Pfizer forges ahead with blood cancer therapy after approval from FDA

Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients.

16 Aug 2023
News Alzheimer's drug donanemab deemed effective in landmark clinical trial

Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.

18 Jul 2023